These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34309066)

  • 21. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
    Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease.
    Lamar M; Foy CML; Beacher F; Daly E; Poppe M; Archer N; Prasher V; Murphy KC; Morris RG; Simmons A; Lovestone S; Murphy DGM
    Neuroimage; 2011 Jul; 57(1):63-68. PubMed ID: 21504795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
    Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
    Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of increased cerebral myo-inositol in the dementia of Down syndrome.
    Shonk T; Ross BD
    Magn Reson Med; 1995 Jun; 33(6):858-61. PubMed ID: 7651126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
    Modrego PJ; Pina MA; Fayed N; Díaz M
    CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis.
    Wang H; Tan L; Wang HF; Liu Y; Yin RH; Wang WY; Chang XL; Jiang T; Yu JT
    J Alzheimers Dis; 2015; 46(4):1049-70. PubMed ID: 26402632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
    Waldman AD; Rai GS
    Neuroradiology; 2003 Aug; 45(8):507-12. PubMed ID: 12879326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.
    Sturrock A; Laule C; Wyper K; Milner RA; Decolongon J; Dar Santos R; Coleman AJ; Carter K; Creighton S; Bechtel N; Bohlen S; Reilmann R; Johnson HJ; Hayden MR; Tabrizi SJ; Mackay AL; Leavitt BR
    Mov Disord; 2015 Mar; 30(3):393-401. PubMed ID: 25690257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study.
    Chaney AM; Lopez-Picon FR; Serrière S; Wang R; Bochicchio D; Webb SD; Vandesquille M; Harte MK; Georgiadou C; Lawrence C; Busson J; Vercouillie J; Tauber C; Buron F; Routier S; Reekie T; Snellman A; Kassiou M; Rokka J; Davies KE; Rinne JO; Salih DA; Edwards FA; Orton LD; Williams SR; Chalon S; Boutin H
    Theranostics; 2021; 11(14):6644-6667. PubMed ID: 34093845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
    Weiss U; Bacher R; Vonbank H; Kemmler G; Lingg A; Marksteiner J
    J Clin Psychiatry; 2003 Mar; 64(3):235-42. PubMed ID: 12716263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S; Mattsson N; Hansson O;
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Joe E; Medina LD; Ringman JM; O'Neill J
    Brain Imaging Behav; 2019 Aug; 13(4):925-932. PubMed ID: 29907927
    [No Abstract]   [Full Text] [Related]  

  • 34. Cerebrospinal Fluid Amyloid Beta, Tau Levels, Apolipoprotein, and
    Piersson AD; Mohamad M; Rajab F; Suppiah S
    Acad Radiol; 2021 Oct; 28(10):1447-1463. PubMed ID: 32651050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
    Huang W; Alexander GE; Chang L; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB
    Neurology; 2001 Aug; 57(4):626-32. PubMed ID: 11524470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-brain patterns of (1)H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies.
    Su L; Blamire AM; Watson R; He J; Hayes L; O'Brien JT
    Transl Psychiatry; 2016 Aug; 6(8):e877. PubMed ID: 27576166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrovascular disease is associated with Alzheimer's plasma biomarker concentrations in adults with Down syndrome.
    Edwards NC; Lao PJ; Alshikho MJ; Ericsson OM; Rizvi B; Petersen ME; O'Bryant S; Aguilar LF; Simoes S; Mapstone M; Tudorascu DL; Janelidze S; Hansson O; Handen BL; Christian BT; Lee JH; Lai F; Rosas HD; Zaman S; Lott IT; Yassa MA; ; Gutierrez J; Wilcock DM; Head E; Brickman AM
    Brain Commun; 2024; 6(5):fcae331. PubMed ID: 39403075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
    J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study.
    Nilsen LH; Melø TM; Saether O; Witter MP; Sonnewald U
    J Neurochem; 2012 Nov; 123(4):532-41. PubMed ID: 22943908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.